Get Even More Bullish on the Dow, Part 4

Editor's note: This is Part 4 of Jim Cramer's review of the prospects for the stocks that make up the Dow 30. Be sure to read Part 1, Part 2 and Part 3.

Merck Not much room to run

Merck(MRK): This one has made its move, and while I would be inclined to name it best of breed and believe that it can climb still higher, the breathtaking run from $25 on the cessation of Vioxx bankruptcy worries doesn't leave it much more room. Plus, it lacks anything really huge to make up for patent expirations. I would be surprised if it can escape the $40s, but a weak dollar could take Merck's earnings up to where $50 is a realistic target.

Microsoft Hungry again

Microsoft(MSFT): It's up nicely, but it isn't done. With Xbox drain over and Xbox gain ahead, with Vista at last shipping and with the cash flow proving big even without it, I think Microsoft won't quit until it's at $35. There have been big changes at Mister Softee over the past year, and I believe this company has gotten hungry again. It has also at last put behind it the fears from antitrust litigation. Steve Ballmer has grown into his job and will fight for shareholders, of which he is a big one.

Pfizer Least favorite

Pfizer(PFE): This one is my least favorite stock in the Dow. It's just a nothing company that's too big and has so little that's exciting about it that if it weren't so low, I would say it would go even lower. But the yield will support it, and I suspect it will finish 2007 right around where it's trading as 2006 ends. New CEO, same old problems. What an uninventive company.